Mycophenolate mofetil (MMF) (brand names CellCept, Myfortic) is a prodrug of mycophenolic acid (MPA), used extensively in transplant medicine. MPA can induce apoptosis of activated T-lymphocytes, which may eliminate clones of cells responding to antigenic stimulation. Second, by depleting guanosine nucleotides, MPA suppresses glycosylation and the expression of some adhesion molecules, thereby decreasing the recruitment of lymphocytes and monocytes into sites of inflammation and graft rejection. Third, by depleting guanosine nucleotides MPA also depletes tetrahydrobiopterin, a co-factor for the inducible form of nitric oxide synthase (iNOS). Mycophenolate mofetil shows inhibitory activity of lymphocyte functions. Mycophenolate mofetil inhibits type 1 collagen expression and enhances MMP-1 expression. Mycophenolate mofetil reduces α-smooth muscle actin gene expression. The total area under the curve of Mycophenolate mofetil showed a 37% reduction in PPI patients vs those treated with no PPIs (P < 0.01), and the maximum peak concentration of Mycophenolate mofetil was 60% lower in the pantoprazole patients (P < 0.001). The Mycophenolate mofetil exposure correlated with the inhibition of IMPDH activity. The co-medication of pantoprazole with MMF significantly influences the compound exposure and immunosuppressive potency of MMF in patients with autoimmune diseases.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 25 mg/mL|
Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil.
Schaier M, et al. Rheumatology (Oxford). 2010 Nov;49(11):2061-7. PMID: 20671023.
Mycophenolate mofetil and its mechanisms of action.
Allison AC, et al. Immunopharmacology. 2000 May;47(2-3):85-118. PMID: 10878285.
|Related Dehydrogenase Products|
Trilostane is an inhibitor of 3β-hydroxysteroid dehydrogenase used in the treatment of Cushing’s syndrome.
Fomepizole is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the initial steps in the metabolism of ethylene glycol and methanol to their toxic metabolites.
Vidofludimus is an orally active and potent dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of 134 nM for human DHODH.
ML323 is a highly potent and selective USP1-UAF1 inhibitor with IC50 of 76 nM.
MK-8245 is an liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) with IC50 of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with anti-diabetic and anti-dyslipidemic efficacy.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.